International Journal of Clinical Research

Objective: To analyze the causes of anemia in lung cancer chemotherapy patients and explore the efficacy and adverse reactions of recombinant human erythropoietin applied to lung cancer chemotherapy patients. Method: Our hospitals HIS system was used to collect 40 lung cancer patients who were clinically and pathologically diagnosed with lung cancer and underwent chemotherapy from May 2020 to April 2022, aged between 40 and 75 years old. They were divided into two groups: the experimental group (N=20) and the control group (N=20), both receiving three cycles of chemotherapy. Anemia during the chemotherapy period was treated with iron. The experimental group received subcutaneous injection of 10000 IU of recombinant human erythropoietin 5 hours after the end of each chemotherapy cycle, in addition to iron therapy, three times a week for 4 consecutive weeks. The treatment effects of the two groups of patients were compared and analyzed. Results The improvement of hemoglobin, red blood cell and hematocrit in patients injected with recombinant human erythropoietin was significantly better than that in patients without injection（P<0.05）. Within 4 weeks of injection of recombinant human erythropoietin, the anemia changes become more pronounced with the prolongation of treatment time. Conclusion: Recombinant human erythropoietin has a certain therapeutic effect on anemia during chemotherapy, and attention should be paid to adverse reactions during medication, and timely monitoring and treatment should be carried out.

Lung cancer, chemotherapy, anemia, erythropoietin